Medtronic Reports 2Q18 Revenue

ORTHOWORLD estimates Medtronic’s 2Q18 revenue at US $739.0MM, +1.8% vs. 2Q17, with 1H18 revenue of $1,526.0MM, +2.8% vs. 1H17.

ORTHOWORLD estimates spine and orthobiologic segment sales and growth on an as-reported basis, as follows. Figures reflect MDT’s FY1Q19 revenue for the period ended 7/28/18.

The Elevate expandable interbody fusion device, Solera Voyager fixation and the Prestige LP cervical disc all contributed incremental revenue for the period.

Leadership noted that surgeon interest in robotic systems overall is driving increased interest in navigation, which is then a tailwind for surgical enabling technologies—which will boost the spinal implant business.

At NASS next month, expect to see the Mazor X Stealth Edition, which is the Mazor X robotic guidance system fully integrated with Stealth navigation; and a navigated Infinity posterior cervical system.

Finally, we heard a few words about orthopaedics! Leadership’s stance is that the overall MDT portfolio is robust, with diversified positions in high-growth market segments—maintaining that growth is the priority. That said, ortho is adjacent to these segments, and MDT is in early stages of looking at approaches like spine/ortho bundles. As RTG Division President Geoff Martha said, “If there is an opportunity for us to be disruptive and scale the [orthopaedic] business in a disruptive way, then we will move more aggressively. We are evaluating that and looking at it from several angles.”

The total knee is presently gathering clinical experience in limited release. The total hip is not yet FDA-cleared.

Source: Medtronic plc